Friday, April 26, 2024
4/26/2024
The central objective of this proposal is to quantify changes in synaptic vesicle (SV) pools and composition over aging and in Alzheimer's Disease Related Dementias such as Lewy body dementia and Parkinson’s dis-ease. SVs mediate neurotransmitter release at the synapse. Their abundance and uniform size have enabled extensive biochemical studies, and ~15% of SV proteins have been linked to CNS diseases, with numerous of them in Alzheimer's Disease Related Dementias and Parkinson’s disease. Yet, no study has analyzed SV sub-types, defined by their vesicular neurotransmitter transporter, or changes in SV composition or pools with aging and in Parkinson’s disease and Alzheimer's Disease Related Dementias such as Lewy body dementia. Most SV proteins are low abundant, with a copy number of <1 per SV. This suggests molecular and functional SV diversity, necessitating a thorough and mechanistic analysis of SV pools and composition. a-Synuclein (aSyn) exists in a SV-bound and a cytosolic state, exchanging between these pools in a dynamic equilibrium. SV-bound aSyn mediates its physiological functions at the synapse. Aggregation of aSyn is a pathological hallmark of Parkinson’s disease, Lewy body dementia and other Alzheimer's Disease Related Dementias, and a large fraction of aSyn aggregates occurs in presynaptic boutons. Pathology has been suggested to be associated with altered aSyn:lipid interactions, and several SV proteins are linked to Parkinson’s disease, Lewy body dementia and other Alzheimer's Disease Related Dementias. Thus, changes in SV lipids or proteins could alter binding of aSyn to SVs. The hypothesis is that reduced SV-binding of aSyn is a precipitating factor for aSyn-linked pathology, and that changes in SV numbers, protein and/or lipid composition account for the reduction in aSyn binding. Guided by our strong preliminary data, revealing reduced SV-binding of aSyn in two Parkinson’s disease mouse models and in brain tissue of Parkinson’s disease and Lewy body dementia patients in addition to an age-dependent reduction of SV density in our humanized aSyn mouse model, this hypothesis will be tested in two specific aims: 1) Determine changes in synaptic vesicle numbers and pools, and 2) Determine changes in SV composition. The study is expected to provide a systematic understanding of the changes in SV pools and composition during aging and in Parkinson’s disease, Lewy body dementia and other Alzheimer's Disease Related Dementias, which lays the foundation to dive further into mechanistic studies. This work is innovative because it will generate high-resolution maps of SVs of different neurotransmitter subtypes over the course of aging and aSyn-linked pathology. The work is significant because it (1) determines for the first time changes in SV composition during aging, (2) determines for the first time the composition of SV subtypes, (3) has important implications for Parkinson’s disease, Lewy body dementia and other Alzheimer's Disease Related Dementias, (4) may provide clues towards cell-type specific vulnerability in Alzheimer's Disease Related Dementias such as Lewy body dementia and in Parkinson’s disease.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
